Company News: Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples
– Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort
– U.S. FDA 510(k) submission for Unyvero LRT BAL Application Cartridge in preparation
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced key data from its successfully completed Unyvero LRT clinical performance evaluation study for BAL samples. Read more…
Company News: Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
– Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing
– Yorkville to provide funding of EUR 1.5 million to Curetis
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Curetis will receive another EUR 6.5 million in gross proceeds under two financing facilities. Read more…
Company News: Curetis Announces Financial Results for the First Three Months of 2019
– Total year-on-year revenue growth of approximately 45%
– Successful implementation of corporate re-organization and significant reduction of cost base
– Exclusive pan-European distribution partnership with A. Menarini Diagnostics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first three months ended March 31, 2019, and provided a business update for 2019. Read more…
